Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of luspatercept in adults and adolescents with alpha-thalassemia
CTR20222846Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Dec 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in alpha thalassemia, alpha-thalassemia intermedia, sponsored by Celgene Corporation. Started Dec 2022; status: active.
02
Drugs
luspatercept
03
Conditions
alpha thalassemiaalpha-thalassemia intermedia
Beyond the preview
Go deeper on CTR20222846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222846.